Treatment strategies include renin‐angiotensin‐aldosterone system (RAAS) blockade with angiotensin‐converting enzyme (ACE) inhibitors (i.e., ramipril and enalapril to delay the progression of renal disease by reducing proteinuria and maintaining kidney function) and angiotensin receptor blockers (ARBs) (i.e., losartan to slow down renal disease progression, with better tolerance in differential patient groups) [15]. This evidence concerns the gene ACE and kidney disorder.